Abstract 257P
Background
GTN comprises a unique group of tumours that originate from trophoblastic tissues which includes Invasive mole, choriocarcinoma and Placental site trophoblastic tumour and with proper treatment low-risk GTN is 100% curable. This study was carried out to evaluate the management outcome of low risk GTN patients to the accepted 1st line treatment regimens followed in the hospital.
Methods
205 patients of gestational trophoblastic disease who were registered at the institute between January 2016 and December 2018 were analysed retrospectively. Risk stratification & Staging was done according to Revised FIGO 2002 staging system. All low risk patients were included the study.
Results
Out of 205 ,46 (22%) patients were diagnosed with GTN (low-risk 43/205(21.5%). 37(86.04%) patients received single agent Methotrexate (weekly) while 4 (9.3%) patients received Actinomycin D (bi-weekly) as first line. Methotrexate/LV was given for 2 patients. 67.5%(n = 25/37) achieved Complete Response (CR) on Methotrexate while 32.4%(n = 12/37) went on to get second line.62.5%(n = 10/16) received ACT-D in second line while multi-drug chemotherapy was given to 5 patients (31%,5/16). CR was achieved in 84.62%(n = 11) in 2nd line while 1 patient went on to get 3rd line chemotherapy. Anemia was the most common complication associated with the disease and treatment.
Conclusions
Low- risk GTN is a highly chemo-sensitive tumor and 100% curable. methotrexate as single agent produced 67.5% of complete remission. Single agent methotrexate is still one of the preferred first-line regimes for low risk GTN.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
The author has declared no conflicts of interest.
Resources from the same session
427P - Sahai: A restorative support to address unmet needs of women with cancer – impact on quality of life
Presenter: Poonam Maurya
Session: Poster display session
Resources:
Abstract
428P - A pilot study on comparative efficacy of tramadol or eutectic mixture of local anaesthetics (prilocaine plus lignocaine) in preventing bone marrow aspiration associated pain
Presenter: Bipinesh Sansar
Session: Poster display session
Resources:
Abstract
429P - Skin pathologic change evaluation of the patients who had EGFR inhibitor-related skin adverse events
Presenter: Sung Yong Oh
Session: Poster display session
Resources:
Abstract
430P - Emetic risk of carboplatin plus pemetrexed is higher than that of carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis
Presenter: Koichi Matsuo
Session: Poster display session
Resources:
Abstract
431P - An in vitro evaluation of CYP2D6 enzymatic inhibition activities of a Chinese herbal medicine formulation (Xiang Bei Yangrong Tang) for the management of cancer-related fatigue
Presenter: Ning Yi Yap
Session: Poster display session
Resources:
Abstract
432P - Chemotherapy induced extravasation: Incidence and possible predictors
Presenter: Shalaka Somayaji
Session: Poster display session
Resources:
Abstract
433P - Prospective outcomes of adolescent and young adult (AYA) patients received treatment from a tertiary cancer hospital in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: Poster display session
Resources:
Abstract
434P - Pneumonitis induced antineoplastic agents: Mortality and risk factors in 129 consecutive cases
Presenter: Sawako Kaku
Session: Poster display session
Resources:
Abstract
435P - Telephonic communication in palliative care for better management of terminal cancer patients in rural India: An NGO based approach
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
436P - Assessing the quality of life of Filipino cancer patients: A survey of Filipino oncologists
Presenter: Frederic Ivan Ting
Session: Poster display session
Resources:
Abstract